Vanguard Group Inc. Raises Stock Position in Savara Inc (NASDAQ:SVRA)

Vanguard Group Inc. grew its position in shares of Savara Inc (NASDAQ:SVRA - Free Report) by 15.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,764,601 shares of the company's stock after purchasing an additional 789,249 shares during the period. Vanguard Group Inc. owned about 4.26% of Savara worth $21,790,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. American Century Companies Inc. lifted its stake in shares of Savara by 110.5% in the 3rd quarter. American Century Companies Inc. now owns 76,169 shares of the company's stock valued at $288,000 after acquiring an additional 39,989 shares during the last quarter. Deutsche Bank AG bought a new stake in shares of Savara in the 3rd quarter valued at about $79,000. Polar Capital Holdings Plc bought a new stake in shares of Savara in the 3rd quarter valued at about $3,780,000. Adage Capital Partners GP L.L.C. lifted its stake in shares of Savara by 30.9% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company's stock valued at $30,008,000 after acquiring an additional 1,874,000 shares during the last quarter. Finally, Affinity Asset Advisors LLC bought a new stake in shares of Savara in the 3rd quarter valued at about $4,347,000. Institutional investors own 87.93% of the company's stock.

Savara Trading Down 5.1 %

SVRA traded down $0.27 during midday trading on Friday, reaching $5.07. 1,175,079 shares of the company's stock traded hands, compared to its average volume of 539,976. The firm has a fifty day moving average of $4.95 and a two-hundred day moving average of $4.36. The stock has a market capitalization of $700.42 million, a price-to-earnings ratio of -15.36 and a beta of 0.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 15.66 and a quick ratio of 15.66. Savara Inc has a 52 week low of $1.69 and a 52 week high of $5.70.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. On average, equities analysts anticipate that Savara Inc will post -0.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. JMP Securities assumed coverage on Savara in a research note on Thursday, February 15th. They issued an "outperform" rating and a $8.00 target price for the company. Piper Sandler upped their price target on Savara from $7.00 to $16.00 and gave the company an "overweight" rating in a research report on Monday, March 4th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $8.20.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.